Campylobacter bacteriophages and uses thereof

Inventors

Sulakvelidze, Alexander

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Assignees

Intralytix Inc

Member
Intralytix
Intralytix

Intralytix is a biotechnology company specializing in bacteriophage-based solutions for controlling pathogenic bacteria in food safety, human and animal health, dietary supplements, environmental sanitation, and veterinary applications. The company utilizes lytic bacteriophages for targeted, non-chemical interventions and operates with in-house cGMP manufacturing, a broad patent portfolio, and ongoing clinical research, applying AI and machine learning in phage discovery and process optimization. Intralytix supports industry and academic progress through conference sponsorships and collaborative projects.

Publication Number

US-12419313-B2

Patent

Publication Date

2025-09-23

Expiration Date


Abstract

The present invention is directed to isolated bacteriophages having specificity and lytic activity against strains of Campylobacter species, methods of using the bacteriophages, progeny and derivatives derived therefrom, to control the growth of Campylobacter species in various settings (e.g., food safety, sanitation, modulating microbiome, prebiotics, probiotics).

Core Innovation

The patent describes isolated lytic Campylobacter-specific bacteriophages deposited under ATCC Deposit Accession Nos. PTA-126839 (CJLB-4), PTA-126840 (CJLB-5), PTA-126841 (CJLB-7), PTA-126842 (CJLB-10), PTA-126843 (CJLB-12), PTA-126844 (CJLB-13), PTA-126845 (CJLB-14), and PTA-126846 (CJLB-15). It also describes variants, progeny, and derivatives of these bacteriophages that maintain lytic activity against Campylobacter species or strains.

The invention addresses Campylobacter colonization and contamination, including environmental contamination and biofilms on food and food-processing equipment. It also indicates needs for removal of antibiotic-resistant or undesirable pathogens and modulation of the GI tract microbiome, while showing selectivity by strong killing of targeted Campylobacter strains and no killing of tested non-Campylobacter species.

In one aspect, the patent provides dietary supplement and/or nutraceutical compositions that include one or more of the deposited lytic bacteriophages or nucleotide-identity variants and are formulated as lyophilized or spray-dried powder, an enteric capsule, or a syrup. For syrup formulations, the bacteriophage is stabilized with an effective amount of an agent selected from a defined group including water-soluble polymers or sugars, cellulose derivatives, low or medium molecular weight polyvinylpyrrolidone, specified glycols, sodium alginate, proteins, lipids, polysaccharides, or mixtures thereof.

Claims Coverage

The partial content includes three independent claims. Across these claims, the coverage centers on dietary supplement and/or nutraceutical compositions containing specific isolated lytic Campylobacter bacteriophages and genome-identity variants, with defined formulation formats and syrup stabilization using an explicitly listed agent group.

Phage-containing dietary supplement and/or nutraceutical composition with specific CJLB deposits and genome-identity variants

A dietary supplement and/or nutraceutical composition comprising one or more of isolated bacteriophages CJLB-4 through CJLB-15, with the corresponding ATCC Deposit Accession Nos., or variants of said bacteriophage having average nucleotide identity over genome of ≥99.9% or ≥95% relative to said bacteriophage, wherein the variants have lytic activity against Campylobacter species or strains, and wherein the composition is formulated as a lyophilized or spray-dried powder, an enteric capsule, or a syrup.

Syrup stabilization with an agent selected from a defined stabilizer group

The dietary supplement and/or nutraceutical composition, wherein the bacteriophage in the syrup is stabilized with an effective amount of an agent selected from the group consisting of a water-soluble polymer or sugar, a derivative of cellulose, a low or medium molecular weight polyvinylpyrrolidone, a glycol with a molecular weight of 4000 or 6000, sodium alginate, a protein, a lipid, a polysaccharide, and a mixture thereof.

Across the independent claims, the patent claims dietary supplement and nutraceutical formulations that contain specified isolated lytic Campylobacter bacteriophages and variants defined by average nucleotide identity thresholds. The claimed formulations are restricted to lyophilized or spray-dried powder, enteric capsules, or syrups, with syrup stabilization defined by an effective amount of an agent selected from a specified stabilizer group.

Stated Advantages

Documented Applications

No documented applications found

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.